PF-03084014 + Gemcitabine + Nab-paclitaxel + PF-03084014 + Gemcitabine + Nab-paclitaxel + Gemcitabine + Nab-paclitaxel
Phase 2Terminated 0 views this week 0 watching💤 Quiet
Interest: 27/100
27
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Metastatic Cancer Pancreas
Conditions
Metastatic Cancer Pancreas
Trial Timeline
Sep 3, 2014 → Nov 6, 2014
NCT ID
NCT02109445About PF-03084014 + Gemcitabine + Nab-paclitaxel + PF-03084014 + Gemcitabine + Nab-paclitaxel + Gemcitabine + Nab-paclitaxel
PF-03084014 + Gemcitabine + Nab-paclitaxel + PF-03084014 + Gemcitabine + Nab-paclitaxel + Gemcitabine + Nab-paclitaxel is a phase 2 stage product being developed by Pfizer for Metastatic Cancer Pancreas. The current trial status is terminated. This product is registered under clinical trial identifier NCT02109445. Target conditions include Metastatic Cancer Pancreas.
What happened to similar drugs?
20 of 20 similar drugs in Metastatic Cancer Pancreas were approved
Approved (20) Terminated (8) Active (0)
Hype Score Breakdown
Clinical
12
Activity
0
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT02109445 | Phase 2 | Terminated |
Competing Products
20 competing products in Metastatic Cancer Pancreas